Table 1.
Subjects | % Positive prevalencea | Optical density (OD) | ||||
---|---|---|---|---|---|---|
Min. | Max. | Median | SD | P valueb | ||
Acute phase | 95.0 | 0.077 | 1.052 | 0.126 | 0.246 | <0.0001 |
3 months of recovery | 54.3 | 0.065 | 0.734 | 0.084 | 0.137 | <0.0001 |
9 months of recovery | 66.7 | 0.061 | 0.382 | 0.081 | 0.067 | <0.0001 |
12 months of recovery | 57.1 | 0.068 | 0.373 | 0.085 | 0.081 | 0.0004 |
Min. the lowest antibody titre of each group of subjects, Max. the highest antibody titre of each group of subjects, Median the median of antibody titre presented as the median OD value of each group of subjects, SD the standard deviation of antibody titre of each group of subjects, NS not significant
aPositive prevalence: the percentage of seropositive individuals who had OD values greater than the cut-off value (mean ± 2 SD of the OD value of healthy controls)
bThe P value of the difference between the mean antibody titre of P. vivax-infected subjects and those in the recovery phase or healthy controls, as calculated using the Mann–Whitney U test